[EN] COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS [FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES NEUROLOGIQUES
摘要:
This disclosure provides compounds of formula (I) and pharmaceutically acceptable salts thereof, that inhibit Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) DYRK1A activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., a neurological disorder) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.
Application of the Photoredox Coupling of Trifluoroborates and Aryl Bromides to Analog Generation Using Continuous Flow
作者:Travis J. DeLano、Upul K. Bandarage、Natalie Palaychuk、Jeremy Green、Michael J. Boyd
DOI:10.1021/acs.joc.6b02408
日期:2016.12.16
aryl bromides with potassium alkyl trifluoroborates, via nickel/photoredox dual catalysis, has been developed for use in continuousflow. This operationally simple protocol is able to form Csp3–Csp2 bonds with significantly reduced reaction times and a broader substrate scope than when conducted in batch. The utility of this method for rapid analog synthesis has been demonstrated by the synthesis of a
3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER
申请人:Abbott Laboratories
公开号:EP1463505A2
公开(公告)日:2004-10-06
US6831175B2
申请人:——
公开号:US6831175B2
公开(公告)日:2004-12-14
[EN] KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE
申请人:ABBOTT LAB
公开号:WO2003051366A2
公开(公告)日:2003-06-26
Compounds having the formula (I), are useful for inhibiting protein kinases and for the treatment of cancer. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.
Kinase inhibitors
申请人:——
公开号:US20030187026A1
公开(公告)日:2003-10-02
Compounds having the formula
1
are useful for inhibiting protein kinases. Also disclosed are compositions which inhibit protein kinases and methods of inhibiting protein kinases in a patient.